{"filing":{"accession_number":"0001731122-26-001351","cik":"0001314052","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"e8011_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001351/e8011_8-k.htm"},"events":[{"id":36430,"run_id":33592,"accession_number":"0001731122-26-001351","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Anavex disclosed completion of clinical conduct of two pharmacology studies (ADME and DDI) for blarcamesine, along with FDA clearance of an IND application in Fragile X syndrome and an upcoming FDA meeting regarding pediatric participants in the Rett syndrome Phase 3 study. These represent material clinical development milestones and regulatory progress for a clinical-stage biopharmaceutical company, but do not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other defined event types. The disclosure centers on operational and clinical advancement rather than financial results or governance matters.","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40841,"accession_number":"0001731122-26-001351","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Anavex disclosed completion of clinical conduct of two pharmacology studies (ADME and DDI) for blarcamesine, along with FDA clearance of an IND application in Fragile X syndrome and an upcoming FDA meeting regarding pediatric participants in the Rett syndrome Phase 3 study. These represent material clinical development milestones and regulatory progress for a clinical-stage biopharmaceutical company, but do not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other defined event types. The disclosure centers on operational and clinical advancement rather than financial results or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:17:15.405204+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40841,"accession_number":"0001731122-26-001351","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Anavex disclosed completion of clinical conduct of two pharmacology studies (ADME and DDI) for blarcamesine, along with FDA clearance of an IND application in Fragile X syndrome and an upcoming FDA meeting regarding pediatric participants in the Rett syndrome Phase 3 study. These represent material clinical development milestones and regulatory progress for a clinical-stage biopharmaceutical company, but do not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other defined event types. The disclosure centers on operational and clinical advancement rather than financial results or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:17:15.405204+00:00","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-10-20"}]}